利鲁唑在两种啮齿动物应激模型中对焦虑和抑郁行为的预防功效

Complex psychiatry Pub Date : 2023-02-03 eCollection Date: 2023-01-01 DOI:10.1159/000529534
Yashika Bansal, Corey Fee, Keith A Misquitta, Sierra A Codeluppi, Etienne Sibille, Robert M Berman, Vladimir Coric, Gerard Sanacora, Mounira Banasr
{"title":"利鲁唑在两种啮齿动物应激模型中对焦虑和抑郁行为的预防功效","authors":"Yashika Bansal, Corey Fee, Keith A Misquitta, Sierra A Codeluppi, Etienne Sibille, Robert M Berman, Vladimir Coric, Gerard Sanacora, Mounira Banasr","doi":"10.1159/000529534","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic stress-related illnesses such as major depressive disorder and post-traumatic stress disorder share symptomatology, including anxiety, anhedonia, and helplessness. Across disorders, neurotoxic dysregulated glutamate (Glu) signaling may underlie symptom emergence. Current first-line antidepressant drugs, which do not directly target Glu signaling, fail to provide adequate benefit for many patients and are associated with high relapse rates. Riluzole modulates glutamatergic neurotransmission by increasing metabolic cycling and modulating signal transduction. Clinical studies exploring riluzole's efficacy in stress-related disorders have provided varied results. However, the utility of riluzole for treating specific symptom dimensions or as a prophylactic treatment has not been comprehensively assessed.</p><p><strong>Methods: </strong>We investigated whether chronic prophylactic riluzole (∼12-15 mg/kg/day p.o.) could prevent the emergence of behavioral deficits induced by unpredictable chronic mild stress (UCMS) in mice. We assessed (i) anxiety-like behavior using the elevated-plus maze, open-field test, and novelty-suppressed feeding, (ii) mixed anxiety/anhedonia-like behavior in the novelty-induced hypophagia test, and (iii) anhedonia-like behavior using the sucrose consumption test. Z-scoring summarized changes across tests measuring similar dimensions. In a separate learned helplessness (LH) cohort, we investigated whether chronic prophylactic riluzole treatment could block the development of helplessness-like behavior.</p><p><strong>Results: </strong>UCMS induced an elevation in anhedonia-like behavior and overall behavioral emotionality that was blocked by prophylactic riluzole. In the LH cohort, prophylactic riluzole blocked the development of helplessness-like behavior.</p><p><strong>Discussion/conclusion: </strong>This study supports the utility of riluzole as a prophylactic medication for preventing anhedonia and helplessness symptoms associated with stress-related disorders.</p>","PeriodicalId":72654,"journal":{"name":"Complex psychiatry","volume":"9 1-4","pages":"57-69"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123365/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.\",\"authors\":\"Yashika Bansal, Corey Fee, Keith A Misquitta, Sierra A Codeluppi, Etienne Sibille, Robert M Berman, Vladimir Coric, Gerard Sanacora, Mounira Banasr\",\"doi\":\"10.1159/000529534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Chronic stress-related illnesses such as major depressive disorder and post-traumatic stress disorder share symptomatology, including anxiety, anhedonia, and helplessness. Across disorders, neurotoxic dysregulated glutamate (Glu) signaling may underlie symptom emergence. Current first-line antidepressant drugs, which do not directly target Glu signaling, fail to provide adequate benefit for many patients and are associated with high relapse rates. Riluzole modulates glutamatergic neurotransmission by increasing metabolic cycling and modulating signal transduction. Clinical studies exploring riluzole's efficacy in stress-related disorders have provided varied results. However, the utility of riluzole for treating specific symptom dimensions or as a prophylactic treatment has not been comprehensively assessed.</p><p><strong>Methods: </strong>We investigated whether chronic prophylactic riluzole (∼12-15 mg/kg/day p.o.) could prevent the emergence of behavioral deficits induced by unpredictable chronic mild stress (UCMS) in mice. We assessed (i) anxiety-like behavior using the elevated-plus maze, open-field test, and novelty-suppressed feeding, (ii) mixed anxiety/anhedonia-like behavior in the novelty-induced hypophagia test, and (iii) anhedonia-like behavior using the sucrose consumption test. Z-scoring summarized changes across tests measuring similar dimensions. In a separate learned helplessness (LH) cohort, we investigated whether chronic prophylactic riluzole treatment could block the development of helplessness-like behavior.</p><p><strong>Results: </strong>UCMS induced an elevation in anhedonia-like behavior and overall behavioral emotionality that was blocked by prophylactic riluzole. In the LH cohort, prophylactic riluzole blocked the development of helplessness-like behavior.</p><p><strong>Discussion/conclusion: </strong>This study supports the utility of riluzole as a prophylactic medication for preventing anhedonia and helplessness symptoms associated with stress-related disorders.</p>\",\"PeriodicalId\":72654,\"journal\":{\"name\":\"Complex psychiatry\",\"volume\":\"9 1-4\",\"pages\":\"57-69\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123365/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Complex psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000529534\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Complex psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000529534","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:重度抑郁症和创伤后应激障碍等慢性应激相关疾病具有共同的症状,包括焦虑、失乐症和无助感。在各种疾病中,神经毒性谷氨酸(Glu)信号传导失调可能是症状出现的原因。目前的一线抗抑郁药物并不直接针对谷氨酸信号转导,许多患者无法从中充分获益,而且复发率很高。利鲁唑通过增加代谢循环和调节信号转导来调节谷氨酸能神经递质。有关利鲁唑对应激相关障碍疗效的临床研究结果各不相同。然而,利鲁唑治疗特定症状或作为预防性治疗的效用尚未得到全面评估:方法:我们研究了慢性预防性利鲁唑(12-15 毫克/千克/天,口服)能否预防小鼠在不可预测的慢性轻度应激(UCMS)诱导下出现行为障碍。我们评估了(i)通过高架-加迷宫、开阔地试验和新奇事物抑制喂食产生的焦虑样行为,(ii)在新奇事物诱导的食欲减退试验中产生的混合焦虑/失神样行为,以及(iii)通过蔗糖消耗试验产生的失神样行为。Z 评分总结了测量相似维度的测试中的变化。在一个单独的习得性无助(LH)队列中,我们研究了慢性预防性利鲁唑治疗是否能阻止无助样行为的发展:结果:UCMS会诱发类似无助行为和整体行为情绪性的上升,而预防性利鲁唑可以阻止这种上升。在LH队列中,预防性利鲁唑可阻止无助样行为的发展:本研究支持利鲁唑作为一种预防性药物,用于预防与应激相关疾病有关的失神和无助症状。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress Models.

Introduction: Chronic stress-related illnesses such as major depressive disorder and post-traumatic stress disorder share symptomatology, including anxiety, anhedonia, and helplessness. Across disorders, neurotoxic dysregulated glutamate (Glu) signaling may underlie symptom emergence. Current first-line antidepressant drugs, which do not directly target Glu signaling, fail to provide adequate benefit for many patients and are associated with high relapse rates. Riluzole modulates glutamatergic neurotransmission by increasing metabolic cycling and modulating signal transduction. Clinical studies exploring riluzole's efficacy in stress-related disorders have provided varied results. However, the utility of riluzole for treating specific symptom dimensions or as a prophylactic treatment has not been comprehensively assessed.

Methods: We investigated whether chronic prophylactic riluzole (∼12-15 mg/kg/day p.o.) could prevent the emergence of behavioral deficits induced by unpredictable chronic mild stress (UCMS) in mice. We assessed (i) anxiety-like behavior using the elevated-plus maze, open-field test, and novelty-suppressed feeding, (ii) mixed anxiety/anhedonia-like behavior in the novelty-induced hypophagia test, and (iii) anhedonia-like behavior using the sucrose consumption test. Z-scoring summarized changes across tests measuring similar dimensions. In a separate learned helplessness (LH) cohort, we investigated whether chronic prophylactic riluzole treatment could block the development of helplessness-like behavior.

Results: UCMS induced an elevation in anhedonia-like behavior and overall behavioral emotionality that was blocked by prophylactic riluzole. In the LH cohort, prophylactic riluzole blocked the development of helplessness-like behavior.

Discussion/conclusion: This study supports the utility of riluzole as a prophylactic medication for preventing anhedonia and helplessness symptoms associated with stress-related disorders.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
期刊最新文献
Epigenetic Alterations in Post-Traumatic Stress Disorder: Comprehensive Review of Molecular Markers. Olfactory Epithelium Infection by SARS-CoV-2: Possible Neuroinflammatory Consequences of COVID-19. Oral Contraceptives and the Risk of Psychiatric Side Effects: A Review Internet-Based Trauma Recovery Intervention for Nurses: A Randomized Controlled Trial Erratum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1